Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology
Top Cited Papers
Open Access
- 11 May 2007
- journal article
- review article
- Published by Wiley in European Journal of Heart Failure
- Vol. 9 (6-7) , 684-694
- https://doi.org/10.1016/j.ejheart.2007.04.003
Abstract
Therapy has improved the survival of heart failure (HF) patients. However, many patients progress to advanced chronic HF (ACHF). We propose a practical clinical definition and describe the characteristics of this condition. Patients that are generally recognised as ACHF often exhibit the following characteristics: 1) severe symptoms (NYHA class III to IV); 2) episodes with clinical signs of fluid retention and/or peripheral hypoperfusion; 3) objective evidence of severe cardiac dysfunction, shown by at least one of the following: left ventricular ejection fraction<30%, pseudonormal or restrictive mitral inflow pattern at Doppler‐echocardiography; high left and/or right ventricular filling pressures; elevated B‐type natriuretic peptides; 4) severe impairment of functional capacity demonstrated by either inability to exercise, a 6‐minute walk test distance<300 m or a peak oxygen uptake1 HF hospitalisation in the past 6 months; 6) presence of all the previous features despite optimal therapy. This definition identifies a group of patients with compromised quality of life, poor prognosis, and a high risk of clinical events. These patients deserve effective therapeutic options and should be potential targets for future clinical research initiatives.Keywords
This publication has 82 references indexed in Scilit:
- A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart FailureJournal of the American College of Cardiology, 2006
- The Seattle Heart Failure ModelCirculation, 2006
- Testing new targets of therapy in advanced heart failure: The design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trialAmerican Heart Journal, 2005
- Aspirin Use in Chronic Heart Failure: What Should We Recommend to the Practitioner?Journal of the American College of Cardiology, 2005
- Peak Oxygen Consumption as a Predictor of Death in Patients With Heart Failure Receiving β-BlockersCirculation, 2005
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart FailureNew England Journal of Medicine, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Coronary artery bypass grafting in severe left ventricular dysfunction: Excellent survival with improved ejection fraction and functional stateJournal of the American College of Cardiology, 1993
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986